Yurut-Caloglu, VuslatCaloglu, MuratKaplan, MustafaInci, Osman2024-06-122024-06-1220091513-7368https://hdl.handle.net/20.500.14551/18440Purpose: To evaluate prognostic factors affecting local control (LC), distant metastases-free survival (DMFS) and overall survival (OS) in bladder carcinoma patients undergoing extravesical extension. Patients and Methods: We retrospectively reviewed the charts of 61 consecutive patients with T3 or T4 bladder carcinoma, treated with definitive radiotherapy from 1999 through 2007. Results: Median age was 69 years and follow-up was 29 months. The LC rate was 33% at 4 years and was increased in patients with a Hb >= 12 g/dl (p=0.003) or a LDH<180 U/L (p=0.021) and in those who received concurrent chemotherapy (p=0.022) on univariate analysis. DMFS was affected by anemia (Hb<12 g/dl) (p=0.039), the absence of chemotherapy (p=0.034) and the presence of newlydiagnosed disease (p=0.01). The OS rate was 19% at 4 years. Non-pure transitional cell carcinoma histological type (p=0.024), anemia (p=0.004), elevated LDH (p=0.003), and newly diagnosed disease (p=0.011) were poor prognostic factors on univariate analyses for OS. Anemia was the only negative prognostic factor for LC (p=0.03), DMFS (p=0.002) and OS (p<0.0001) on multivariate analysis. Conclusion: Pre-treatment Hb level is the most important prognostic factor in patients treated with definitive radiotherapy, so that anemia may act as a surrogate biological marker for aggressive disease.eninfo:eu-repo/semantics/closedAccessAnemiaBladder CancerPrognostic FactorChemotherapy/RadiotherapyTurkeyTransitional-Cell-CarcinomaExternal-Beam RadiotherapyRadical CystectomyUrinary-BladderLocal-ControlProgressive TumorsPrognostic-FactorsCancerTherapySurvivalArticle10611511157Q4WOS:00027723760003620192602